ClinicalTrials.gg
CompletedNCT00143338Updated Feb 12, 2008

To Examine the Lung When People With Diabetes Take an Inhaled Form of Insulin, Compared to Subcutaneous Insulin.

A Phase 2 interventional study of Inhaled insulin in Diabetes Mellitus, Type 2, sponsored by Pfizer. Completed at 2 sites in United States. Open to participants aged 30 Years to 55 Years. Per ClinicalTrials.gov, last updated 2008-02-12.

Sponsored by Pfizer · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
20
Allocation
Non-randomized
Ages
30 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 54 studies testing insulin in Diabetes Mellitus, Type 2 — 3 open to participants now, 5 under way, 1 of them phase 3. Insulin · Diabetes Mellitus, Type 2.

Enrollment
40th of 54
20 · median 60
Started
2004
with 1 other
Phase 2
11 of 54
none open now
Registered
4th of 54
by date
Lead sponsor
3 of 54
Pfizer

Among the 54 studies testing insulin in Diabetes Mellitus, Type 2, this one is the 40th largest by enrollment, is one of 2 that started in 2004, is one of 11 in phase 2, and was the 4th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

3 of the 54 studies testing insulin in Diabetes Mellitus, Type 2 are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About insulin

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 30 Years to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies testing insulin in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

To examine the lung when people with diabetes take an inhaled form of insulin, compared to subcutaneous insulin.

03

Conditions studied

  • Diabetes Mellitus, Type 2
04

Who can participate

Ages eligible
30 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Type 2 Diabetes Mellitus
  • Normal lung function

Exclusion criteria

Exclusion Criteria:

  • Smokers
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants

Interventions

06

What researchers measure

Primary outcomes

  1. To assess in patients with type 2 diabetes mellitus the effects, if any, on lung lining fluid cell count and differential within subjects after 12 weeks of inhaled insulin therapy compared to 12 weeks of subcutaneous short-acting therapy.

Secondary outcomes

  1. (1) Albumin and fibrinogen concentrations, and airway appearance in the above subjects. (2) routine safety, tolerance, and efficacy in the above subjects.

07

Study locations

2 sites
  • Pfizer Investigational Site
    Fresno, California, United States
  • Pfizer Investigational Site
    San Antonio, Texas, United States
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2004 and a completion of Dec 2006. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 31, 2005
First posted
Sep 2, 2005
Start
Nov 2004
CompletionActual
Dec 2006
Last update
Feb 12, 2008
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 12, 2008, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00143338
Lead sponsor
Pfizer
Collaborators
Sanofi
First posted
Sep 2, 2005
Start date
Nov 2004
Completion
Dec 2006
Last update
Feb 12, 2008

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2008. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Insulin

Start the discussion